Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
02
2020
accepted:
03
08
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Ewing sarcoma (EwS) is a rare, aggressive solid tumor of childhood, adolescence and young adulthood associated with pathognomonic EWSR1-ETS fusion oncoproteins altering transcriptional regulation. Genome-wide association studies (GWAS) have identified 6 common germline susceptibility loci but have not investigated low-frequency inherited variants with minor allele frequencies below 5% due to limited genotyped cases of this rare tumor. We investigated the contribution of rare and low-frequency variation to EwS susceptibility in the largest EwS genome-wide association study to date (733 EwS cases and 1,346 unaffected controls of European ancestry). We identified two low-frequency variants, rs112837127 and rs2296730, on chromosome 20 that were associated with EwS risk (OR = 0.186 and 2.038, respectively; P-value < 5×10-8) and located near previously reported common susceptibility loci. After adjusting for the most associated common variant at the locus, only rs112837127 remained a statistically significant independent signal (OR = 0.200, P-value = 5.84×10-8). These findings suggest rare variation residing on common haplotypes are important contributors to EwS risk. Motivate future targeted sequencing studies for a comprehensive evaluation of low-frequency and rare variation around common EwS susceptibility loci.
Sections du résumé
BACKGROUND
Ewing sarcoma (EwS) is a rare, aggressive solid tumor of childhood, adolescence and young adulthood associated with pathognomonic EWSR1-ETS fusion oncoproteins altering transcriptional regulation. Genome-wide association studies (GWAS) have identified 6 common germline susceptibility loci but have not investigated low-frequency inherited variants with minor allele frequencies below 5% due to limited genotyped cases of this rare tumor.
METHODS
We investigated the contribution of rare and low-frequency variation to EwS susceptibility in the largest EwS genome-wide association study to date (733 EwS cases and 1,346 unaffected controls of European ancestry).
RESULTS
We identified two low-frequency variants, rs112837127 and rs2296730, on chromosome 20 that were associated with EwS risk (OR = 0.186 and 2.038, respectively; P-value < 5×10-8) and located near previously reported common susceptibility loci. After adjusting for the most associated common variant at the locus, only rs112837127 remained a statistically significant independent signal (OR = 0.200, P-value = 5.84×10-8).
CONCLUSIONS
These findings suggest rare variation residing on common haplotypes are important contributors to EwS risk.
IMPACT
Motivate future targeted sequencing studies for a comprehensive evaluation of low-frequency and rare variation around common EwS susceptibility loci.
Identifiants
pubmed: 32881892
doi: 10.1371/journal.pone.0237792
pii: PONE-D-20-05330
pmc: PMC7470401
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237792Subventions
Organisme : NCI NIH HHS
ID : U24 CA055727
Pays : United States
Déclaration de conflit d'intérêts
The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Leidos Biomedical Research Inc. and Information Management Services, Inc. provided salaries for authors J.M., E.K., C.L.D., L.B., K.J., M.M., K.W., and W.Z. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.
Références
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cancer. 2009 Aug 1;115(15):3526-36
pubmed: 19548262
Cancer Res. 2016 Sep 1;76(17):5040-53
pubmed: 27364557
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54
pubmed: 18626011
Cancer Cell. 2007 May;11(5):421-9
pubmed: 17482132
Nat Genet. 2015 Sep;47(9):1073-8
pubmed: 26214589
J Oncol. 2019 May 23;2019:7091815
pubmed: 31239841
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Occup Environ Med. 2008 Jan;65(1):56-60
pubmed: 17634245
BMC Bioinformatics. 2020 Jan 10;21(1):14
pubmed: 31924160
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
pubmed: 11189684
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
PLoS One. 2008 Jul 02;3(7):e2551
pubmed: 18596976
Nat Commun. 2019 Sep 11;10(1):4128
pubmed: 31511524
PLoS One. 2009;4(3):e4932
pubmed: 19305498
Nat Genet. 2012 Feb 12;44(3):323-7
pubmed: 22327514
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
EBioMedicine. 2018 Jul;33:88-93
pubmed: 29937070
Cancer Lett. 2018 Aug 28;430:88-96
pubmed: 29778568
Nature. 1992 Sep 10;359(6391):162-5
pubmed: 1522903
Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):245-255
pubmed: 31243105
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
PLoS Genet. 2014 Apr 17;10(4):e1004234
pubmed: 24743097
PLoS One. 2011 Apr 29;6(4):e19305
pubmed: 21559395
Cancer. 2002 May 1;94(9):2490-501
pubmed: 12015775
Bioinformatics. 2018 Mar 1;34(5):887-889
pubmed: 28968746
Br J Cancer. 2006 Dec 4;95(11):1603-7
pubmed: 17106438
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Nat Commun. 2018 Aug 9;9(1):3184
pubmed: 30093639
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Oncogene. 2010 Aug 12;29(32):4504-16
pubmed: 20543858
N Engl J Med. 1983 Aug 25;309(8):496-8
pubmed: 6877319
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734